SPECIALTY QUANTITY LIMIT PROGRAM

ILUMYA (tildrakizumab-asmn)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.


II. COVERED QUANTITIES

| Medication | Standard Limit | Exception Limit* | FDA-recommended dosing |
|-----------------------------|------------------------|------------------------|---|
| llumya 100 mg/mL syringe | 1 syringe per 12 weeks | 2 syringes per 28 days | 100 mg at weeks 0, 4, and every 12 weeks thereafter |

^{*}Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCES

1. Ilumya [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; August 2018.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of